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Research
Parkinson’s disease (PD) is a complex disease 
for which a number of genetic and environ-
mental risks have been identified. Twin stud-
ies suggest that environmental risk factors may 
be particularly important in patients whose ill-
ness begins after 50 years of age (Tanner et al. 
1999). Although much of the research into 
environmental contributors to PD has focused 
on pesticides, other toxicants have been 
explored as well (Elbaz and Moisan 2008; Lai 
et al. 2002). Lead is known to disrupt dop-
aminergic function in experimental studies 
and can induce oxidative stress (Ercal et al. 
2001), which is a candidate hypothesis for the 
etiology of PD (Jenner 2003). The assessment 
of exposure to lead, particularly cumulative 
exposure, however, can be difficult.
Lead can be measured easily in blood, 
but its half-life is approximately 30 days, ren-
dering this biomarker a better indicator of 
recent exposure than of cumulative exposure. 
Cumulative exposure, however, might be more 
relevant than recent exposure for the develop-
ment of PD. Prior studies of lead and PD have 
generally relied on self-reported exposure or on 
work histories from which cumulative expo-
sures are reconstructed. Although these studies 
have suggested an association with cumulative 
exposure to lead, biomarkers of cumulative 
exposure could provide a more robust expo-
sure measure. Circulating lead is deposited 
in bone, where it has a half-life on the order 
of years to decades, making it an excellent 
biomarker of cumulative lead exposure (Hu 
et al. 1998). Bone lead can be assessed with 
the K-shell X-ray fluorescence (KXRF) tech-
nique, but only one study has examined the 
association of this biomarker with PD, finding 
a suggestive but not quite significant [odds 
ratio (OR) = 1.62; 95% confidence intervals 
(CI), 0.83–3.17] association in an analysis 
involving 121 PD patients and 414 controls 
(Coon et al. 2006). We examined the associa-
tion between cumulative exposure to lead—as 
measured by lead in bone with KXRF—and 
odds of PD in a case–control study based in 
Boston, Massachusetts.
Materials and Methods
Study population. Between 2003 and 2007, 
we recruited PD patients from four different 
movement disorders clinics in the Boston, 
Massachusetts, area: Boston University Medical 
Center (BUMC), Brigham and Women’s 
Hospital (BWH), Beth Israel Deaconess 
Medical Center (BIDMC), and Harvard 
Vanguard Medical Associates (HVMA). Cases 
from these four sites were confirmed by move-
ment disorder specialists using the U.K. brain 
bank criteria (Hughes et al. 1992). In addi-
tion, the patients had to have two evaluations 
by a neurologist at least 6 months apart. We 
included additional cases from the Normative 
Aging Study (NAS), a Boston-based, longitudi-
nal study of aging in men that was established 
in 1963 (Bell et al. 1966). From 1991 through 
1999, 876 NAS participants had their bone 
lead measured with KXRF, as described previ-
ously (Weisskopf et al. 2007). Case ascertain-
ment in the NAS was by self-report of having 
been diagnosed with PD by a physician—all 
NAS cases were taking PD medications.
Controls were recruited from among 
spouses, in-laws, and friends of the cases who 
had been recruited from the movement dis-
orders clinics; through community advertise-
ment; and from participants in the Harvard 
Cooperative Program on Aging (HCPOA) 
research participant cohort. The HCPOA is 
a program of the Hebrew SeniorLife Institute 
for Aging Research in Boston that maintains a 
registry of ethnically diverse elderly volunteers 
who have agreed to participate in research 
studies. We additionally included as a control 
any NAS participant without PD who was 
born in the same year as an NAS case and who 
had a bone lead measurement within 1 year of 
an NAS case. These restrictions were applied 
because there is a wide range of ages and years 
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Ba c k g r o u n d: Research using reconstructed exposure histories has suggested an association 
between heavy metal exposures, including lead, and Parkinson’s disease (PD), but the only study 
that used bone lead, a biomarker of cumulative lead exposure, found a nonsignificant increase in 
risk of PD with increasing bone lead.
oBjectives: We sought to assess the association between bone lead and PD.
Me t h o d s : Bone lead concentrations were measured using 109Cd excited K-shell X-ray fluorescence 
from 330 PD patients (216 men, 114 women) and 308 controls (172 men, 136 women) recruited 
from four clinics for movement disorders and general-community cohorts. Adjusted odds ratios 
(ORs) for PD were calculated using logistic regression.
re s u l t s: The average age of cases and controls at bone lead measurement was 67 (SD = 10) and 69 
(SD = 9) years of age, respectively. In primary analyses of cases and controls recruited from the same 
groups, compared with the lowest quartile of tibia lead, the OR for PD in the highest quartile was 
3.21 [95% confidence interval (CI), 1.17–8.83]. Results were similar but slightly weaker in analyses 
restricted to cases and controls recruited from the movement disorders clinics only (fourth-quartile 
OR = 2.57; 95% CI, 1.11–5.93) or when we included controls recruited from sites that did not also 
contribute cases (fourth-quartile OR = 1.91; 95% CI, 1.01–3.60). We found no association with 
patella bone lead.
co n c l u s i o n s: These findings, using an objective biological marker of cumulative lead exposure 
among typical PD patients seen in our movement disorders clinics, strengthen the evidence that 
cumulative exposure to lead increases the risk of PD.
key w o r d s : biomarker, bone lead, case–control study, epidemiology, humans, metals, risk factor. 
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of bone lead measurements among men in 
the NAS cohort and because there are age and 
calendar year trends in bone lead levels (Kim 
et al. 1997).
We recruited a total of 344 PD patients 
and 324 controls. Fourteen PD patients and 
16 controls did not have valid tibia bone 
lead measurements and were excluded; we 
included a total of 330 cases and 308 con-
trols in the analyses. Of the cases, 163 were 
recruited from BUMC, 75 from BWH, 48 
from BIDMC, 40 from HVMA, and 4 from 
the NAS cohort. Among the controls, 69 
were recruited from among spouses, in-laws, 
and friends of the cases from the movement 
disorders clinics; 97 were NAS participants; 
and the remaining 142 controls were from 
the HCPOA or recruited through community 
advertisement. Only one control did not have 
a valid patella bone lead measurement, but six 
cases and five other controls did not have lead 
measurements taken at their patella. Thus, we 
included 338 cases and 318 controls in our 
analyses of patella bone lead and PD.
This study was approved by the Human 
Research Committee of the Harvard School of 
Public Health, the BWH, and the VA Boston 
Healthcare System. Written informed consent 
was obtained from all participants.
Bone lead levels measured by KXRF. 
Bone lead measurements were taken at two 
anatomical sites with a KXRF instrument. 
When we began measuring bone lead, we 
used an instrument developed by ABIOMED 
(Danvers, MA). A technical description and 
validity specifications of this instrument have 
been published elsewhere (Aro et al. 2000; 
Burger et al. 1990; Hu et al. 1990). In 1999, 
we replaced our prototype ABIOMED instru-
ment with an upgraded instrument designed 
to improve measurement precision, with 
changes in the cadmium radiation source, 
adjustments to the geometry of the measure-
ment procedure, and upgrades in both the 
software and specific hardware components 
of the system (Aro et al. 1994). Thirty-minute 
measurements were taken of the left tibia and 
patella, after each region had been washed 
with a 50% solution of isopropyl alcohol. The 
tibia was measured at midshaft—the midpoint 
between the tibial plateau and the medial mal-
leolus. The KXRF beam collimator was sited 
perpendicular to the flat bony surface of the 
tibia and at 30° in the lateral direction for the 
patella. Tibia and patella bone lead measure-
ments with estimated uncertainties > 10 and 
15 μg/g bone, respectively, were excluded, as 
described above, because these measurements 
usually reflect excessive subject movement dur-
ing the measurement.
Tibia bone is primarily cortical bone, in 
which lead has a lower turnover rate—esti-
mated at a half-life of > 20 years in previous 
studies (Kim et al. 1997), which makes it a 
good surrogate for lifetime exposure. In con-
trast, patella lead has a half-life of less than a 
decade, because it is trabecular bone, so these 
two exposure indices can help determine the 
relevant exposure interval for any association.
Statistical analyses. We used logistic 
regression to estimate ORs of PD by bone 
lead concentration and their 95% CIs, adjust-
ing for age, age squared, sex, race (white/
other), pack-years of cigarette smoking, edu-
cation (high school diploma or less, some col-
lege, college graduate, graduate school), and 
recruitment site. After accounting for age, age 
squared, sex, race, pack-years of smoking, and 
education, bone lead levels in the HCPOA 
and community controls were virtually the 
same as levels among the controls who were 
recruited from BUMC (tibia difference: –0.58 
μg/g bone mineral, p = 0.79; patella differ-
ence: –0.90 μg/g bone mineral, p = 0.74). 
Thus, HCPOA and community controls were 
grouped with subjects recruited from BUMC. 
Cases and controls from the NAS had higher 
bone lead levels than did other participants in 
our study, which, because of the much larger 
control-to-case ratio among NAS participants 
compared with other recruitment sites in our 
steady, biases downward the crude association 
between bone lead and PD. The inclusion 
of the terms for recruitment site controls for 
this bias. For variables with missing data for 
some participants (never > 9% for any vari-
able in any model), separate missing catego-
ries were entered into the models. Because 
the use of missing indicator categories can 
possibly introduce bias, we ran the same mod-
els using the multiple imputation procedure 
in SAS (PROC MI and MIANALYZE) to 
impute missing values and combine results 
from ten imputations as has been described 
elsewhere (Graham 2009). Results from these 
models differed little from our main analyses, 
so only the latter are presented. Bone lead was 
categorized into quartiles separately for each 
lead–PD model; thus, the numbers of cases 
and controls by quartile differ across mod-
els. Tests for trend were assessed by includ-
ing a continuous term in the model created 
by assigning to each bone lead category the 
median of concentrations in that category. 
As sensitivity analyses, we also ran models 
using conditional logistic regression with 







sites with cases 
(n = 166)
Controls from 
  movement disorders 
clinics (n = 69)
Age (years) at KXRF (mean ± SD) 66.5 ± 9.5 69.4 ± 8.8 68.8 ± 7.2 65.4 ± 9.0
Years since diagnosis (mean ± SD)   6.9 ± 5.8 NA NA NA
Pack-years, median (25th–75th percentile) 0 (0–8) 0.8 (0–17.6) 2.3 (0–19.5) 0 (0–6.5)
Male [n (%)] 216 (65.5) 172 (55.8) 126 (75.9) 29 (42.0)
Nonwhite race [n (%)] 35 (10.6) 52 (16.9) 15 (9.0) 14 (20.3)
Education [n (%)]
≤ High school graduate 45 (13.6) 74 (24.0) 51 (30.7) 6 (8.7)
Some college or trade school 42 (12.7) 70 (22.7) 39 (23.5) 15 (21.7)
College graduate 97 (29.4) 78 (25.3) 35 (21.1) 17 (24.6)
Postgraduate 123 (37.3) 70 (22.7) 28 (16.9) 19 (27.5)
Missing 23 (7.0) 16 (5.2) 13 (7.8) 12 (17.4)
Recruitment site [n (%)]      
BUMC 163 (49.4) 39 (11.0) 39 (23.5) 39 (56.5)
BWH 75 (22.7) 13 (3.7) 13 (7.8) 13 (18.8)
BIDMC 48 (14.6) 4 (1.1) 4 (2.4) 4 (5.8)
HVMA 40 (12.1) 13 (3.7) 13 (7.8) 13 (18.8)
NAS 4 (1.2) 97 (27.4) 97 (58.4) 0
HCPOA 0 135 (38.1) 0 0
Community 0 7 (2.0) 0 0
NA, not applicable.
Table 2. Baseline characteristics of controls by quartilea of tibia bone lead.
Quartile
Characteristic First (n = 74) Second (n = 83) Third (n = 74) Fourth (n = 77)
Tibia lead [µg/g bone mineral] ≤ 5 5.2–10.4 11.0–19.0 ≥ 19.1
Age (years) at KXRF (mean ± SD) 64.4 ± 11.2 70.5 ± 8.2 71.0 ± 7.1 71.7 ± 6.2
Pack-years, median (25th–75th percentile) 0 (0–3.7) 0 (0–11.0) 6.3 (0–18.9) 6.3 (0–28.3)
Male [n (%)] 22 (29.7) 42 (50.6) 46 (62.2) 62 (80.5)
Nonwhite race [n (%)] 22 (29.7) 14 (16.9) 10 (13.5) 6 (7.8)
Education [n (%)]
≤ High school graduate 8 (10.8) 11 (13.3) 14 (18.9) 41 (53.3)
Some college or trade school 13 (17.6) 16 (19.3) 24 (32.4) 17 (22.1)
College graduate 19 (25.7) 29 (34.9) 18 (24.3) 12 (15.6)
Postgraduate 26 (35.1) 22 (26.5) 17 (23.0) 5 (6.5)
Missing 8 (10.8) 5 (6.0) 1 (1.4) 2 (2.6)
aDifferent from quartiles used in some of the models (see “Materials and Methods”).Cumulative lead exposure and Parkinson’s disease
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stratification by recruitment site. The results 
of these models were similar to logistic regres-
sion models, so only the latter are presented. 
A spurious association between lead and risk 
of PD could result if lead is associated with 
duration of survival with PD. Therefore, we 
used linear regression to assess this associa-
tion. In these analyses, we regressed duration 
of PD, in years, on bone lead and all other 
covariates. The threshold for statistical sig-
nificance was set at p < 0.05. All analyses were 
conducted with SAS software (version 9; SAS 
Institute, Inc., Cary, NC).
Results
The overall mean ± SD patella and tibia bone 
lead concentrations were 13.6 ± 15.9 and 
10.7 ± 12.1 μg/g bone mineral, respectively. 
Table 1 shows the distribution of covariates 
among the cases, all controls from all sites 
with cases, and the subset of controls recruited 
from the movement disorders clinic sites. A 
majority of controls came from the NAS and 
HCPOA. Table 2 shows the distribution of 
covariates by tibia bone lead quartile among 
all controls. Older age, higher percentage of 
men, and lower educational attainment with 
increasing tibia lead quartile reflects in part the 
greater representation of NAS participants—
who are all male, tend to be older with lower 
educational attainment, and have higher bone 
lead levels—among the controls.
Because we recruited no PD cases from 
the HCPOA or through community adver-
tisement and therefore could not include a 
term for this group in our models to con-
trol for potential confounding introduced by 
unmeasured differences among this group, 
our primary analyses excluded these controls. 
In these analyses (Table 3), the odds of PD 
were significantly higher among those in 
the highest quartile of tibia bone lead than 
among those in the lowest (OR = 3.21; 95% 
CI, 1.17–8.83; p for trend = 0.02). In the 
analyses that were restricted to cases who 
were recruited from the movement disorders 
clinics and their controls (spouse/in-law/
friend) (Table 3), we obtained similar results, 
with an OR of 2.57 (95% CI, 1.11–5.93; 
p for trend = 0.03) for PD among those in 
the highest versus the lowest quartile. In the 
analyses of all cases and controls, the results 
were also similar although slightly weaker 
(OR = 1.91; 95% CI, 1.01–3.60; p for 
trend = 0.06). This finding suggests some 
negative confounding that we could not con-
trol for because we recruited no cases from 
the HCPOA or through community adver-
tisement. We found no association between 
patella bone lead and PD (Table 4).
We found no association between duration 
of PD and either patella bone lead (–0.48 years 
per SD increase in patella bone lead; p = 0.37) 
or tibia bone lead (0.12 years per SD increase 
in tibia bone lead; p = 0.79). The association 
between tibia bone lead concentration and 
PD was slightly stronger when we restricted 
cases to those with less than the median PD 
duration (5.5 years) than when we restricted 
it to those with more than the median PD 
duration. When we excluded HCPOA and 
community advertisement controls from the 
analyses, the OR for PD among those in the 
highest compared with lowest quartile was 
3.34 (95% CI, 1.06–10.55) for the shorter 
duration cases and 2.81 (95% CI, 0.86–9.17) 
for the longer duration cases. We found little 
difference in results when we stratified by sex 
or by education (at least college graduate vs. 
less education; data not shown).
Discussion
In this large case–control study with bio-
marker data on cumulative exposure to lead 
and more than twice as many cases as the 
only previous study with such biomarker data 
(Coon et al. 2006), we found increasing odds 
of PD with increasing tibia (cortical) bone 
lead, which has a half-life of decades (Kim 
et al. 1997). The positive association with 
tibia bone lead remained fairly consistent 
whether analyses excluded HCPOA and com-
munity advertisement controls, included only 
movement disorders clinic cases and their 
spouse/in-law/friend controls, or included all 
cases and controls. Our analyses adjusted for 
age, sex, race, smoking, and education; thus, 
the association with tibia lead appears to be 
independent of these factors. We found no 
association between patella (trabecular) bone 
lead and PD. The half-life of lead in trabecu-
lar bone is approximately 8 years, whereas that 
in cortical bone is several decades (Kim et al. 
1997). Thus, cortical bone lead represents a 
cumulative exposure marker for lead exposure 
that is more long term than is trabecular bone 
lead. The lack of association between patella 
lead and PD therefore may suggest that the 
relevant exposure window for lead driving 
the association with PD is many years, even 
decades, before PD onset.
Although exposure to metals in general 
has been considered as a possible etiologic fac-
tor in the development of PD, few studies, 
other than a few case series and a case report, 
have specifically focused on lead (Kuhn et al. 
1998; Sanz et al. 2007; Winkel et al. 1995). 
A case–control study in Belgium found 76% 
elevated odds of PD among those self-report-
ing lead exposure, but this was not signifi-
cant (Pals et al. 2003). A case–control study 
Table 3. Adjusteda OR for PD by quartile of tibia bone lead.
All cases, and spouse/in-law/friend  
and NAS controlsb
Movement disorders clinic cases only,  
and only spouse/in-law/friend controlsc All cases and controls
Quartile Lead (µg/g) Cases/controls OR (95% CI) Lead (µg/g) Cases/ controls OR (95% CI) Lead (µg/g) Cases/ controls OR (95% CI)
First < 3.1 90/30 Reference < 1 68/24 Reference < 3.1 90/66 Reference
Second 3.5–9.6 101/31 1.36 (0.70–2.63) 1.7–7.0 86/18 1.48 (0.72–3.04) 3.5–9.0 92/64 1.30 (0.76–2.23)
Third 10.0–17.0 85/33 1.90 (0.90–4.01) 7.8–13.1 88/16 1.91 (0.91–4.00) 9.6–16.0 91/76 1.37 (0.80–2.36)
Fourth > 17.3 54/72 3.21 (1.17–8.83) > 13.9 84/11 2.57 (1.11–5.93) > 16.0 57/102 1.91 (1.01–3.60)
p-Trend 0.02 0.03 0.06
aAdjusted for age, age squared, sex, race, pack-years of cigarette smoking, education, and recruitment site. bExcluding HCPOA and community advertisement controls. cExcluding 
NAS cases and NAS, HCPOA, and community advertisement controls.
Table 4. Adjusteda OR for PD by quartile of patella bone lead.b
All cases, and spouse/in-law/friend  
and NAS controlsc
Movement disorders clinic cases only,  
and only spouse/in-law/friend controlsd All cases and controls
Quartile Lead (µg/g) Cases/ controls OR (95% CI) Lead (µg/g) Cases/ controls OR (95% CI) Lead (µg/g) Cases/ controls OR (95% CI)
First  < 2.7 101/29 Reference  < 1 77/21 Reference  < 2.7 101/62 Reference
Second 3.5–11.0 89/32 0.98 (0.50–1.93) 1.7–7.8 86/24 1.04 (0.51–2.14) 3.5–11.0 89/74 1.12 (0.66–1.91)
Third 11.3–20.9 100/35 1.71 (0.81–3.62) 8.7–15.7 83/14 1.44 (0.64–3.29) 11.3–20.0 94/69 1.37 (0.80–2.39)
Fourth  > 20.9 48/77 1.15 (0.45–2.93)  > 16.5 88/17 1.20 (0.52–2.76)  > 20.0 54/113 1.03 (0.54–1.95)
p-Trend 0.42 0.47 0.83
aAdjusted for age, age squared, sex, race, pack-years of cigarette smoking, education, and recruitment site. bBecause of availability of valid patella bone lead measurements, as 
described in “Materials and Methods,” eight more cases and six fewer controls in the total sample had patella bone lead analyses than had tibia bone lead analyses. cExcluding 
HCPOA and community advertisement controls. dExcluding NAS cases and NAS, HCPOA, and community advertisement controls.Weisskopf et al.
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within the Henry Ford Health System used 
occupational histories to estimate exposures 
to different metals and found significantly 
increased odds of PD with more than 20 years 
of combined exposure to lead and copper 
(OR = 5.24; 95% CI, 1.59–17.21) and lead 
and iron (OR = 2.83; 95% CI, 1.07–7.50) 
compared with those with no exposure (Gorell 
et al. 1997). A follow-up case–control study 
in the Henry Ford Health System assessed 
blood and tibia bone lead levels and also 
reconstructed exposures based on occupational 
history: Coon et al. (2006). Those authors 
created a model that combined all these mea-
sures to estimate lifetime lead exposure and 
found that, compared with those in the lowest 
quartile of this metric, those in the highest 
quartile had an OR of PD of 2.27 (95% CI, 
1.13–4.55). When they considered only tibia 
bone lead, their results (OR = 1.62; 95% CI, 
0.83–3.17) were less robust than those of our 
present study, possibly because of the smaller 
number of subjects in the earlier study. The 
mean concentrations of tibia lead were similar 
between the prior study and ours.
There are several mechanisms by which 
lead could be related to the development of 
PD. There is considerable experimental evi-
dence that lead disrupts the dopaminergic 
system. Acutely, lead increases spontaneous 
dopamine release, inhibits depolarization-
evoked dopamine release, decreases dopamine 
neuron spontaneous activity in vivo, and can 
alter dopamine-dependent behaviors (Cory-
Slechta 1997; Minnema et al. 1986; Tavakoli-
Nezhad et al. 2001). Studies have indicated 
that dopamine synthesis, turnover, and uptake 
in the midbrain and basal ganglia are decreased 
after lead exposure (Govoni et al. 1979; Jadhav 
and Ramesh 1997; Lasley 1992; Lucchi et al. 
1981; Missale et al. 1984), as is dopamine 
D1/D2 receptor expression (Gedeon et al. 
2001). In addition, excessive oxidative toxicity 
is a candidate etiologic factor for PD (Jenner 
2003), and lead exposure is a well-known 
prooxidant, inducing oxidative stress through 
direct actions on cell membranes, inter  actions 
with hemoglobin or δ-aminolevulinic acid 
dehydratase, or depletion of antioxidant 
defenses (Ercal et al. 2001).
A strength of our study is the use of bone 
lead measurements as biomarkers of cumula-
tive lead exposure over many years. A limita-
tion of this study is that we measured these 
levels several years after the diagnosis of PD, 
leading to the possibility that the disease state 
could affect the bone lead levels. However, we 
used bone lead levels as the biomarker rather 
than blood lead levels, and the long half-life 
of lead in bone means that the assessment of 
exposure even several years after diagnosis will 
still reflect to some extent exposures prior to 
disease diagnosis. Furthermore, it is unlikely 
that external lead exposures would become 
higher among PD patients after disease diag-
nosis. If lead exposure caused longer survival 
with PD, then this could bias our results, but 
this seems unlikely, and bone lead was not 
associated with PD duration in our data.
Having bone lead measurements from 
both tibia (cortical) and patella (trabecular) 
bone is an additional strength of our study 
that helps to address the concern that osteo-
porosis and osteopenia, which are common 
in PD (Invernizzi et al. 2009), could differen-
tially affect the lead levels measured in cases 
and controls and bias the results. Although 
osteoporosis and osteopenia are the result of 
bone loss, the most important factor influenc-
ing bone lead content is the rate of bone for-
mation rather than the rate of bone resorption 
(Hu et al. 1998). As bone is resorbed, the lead 
concentration in the remaining bone (on a per 
gram of bone mineral basis) should remain 
the same. If new bone formation were to slow 
more in PD patients than in controls, then 
PD patients would be forming less new bone 
in recent years compared with controls—and 
because external exposures to lead have been 
much lower in recent years than in the past, 
one would expect the overall concentration of 
lead in bone to decline less in the cases than in 
controls. However, because bone lead appears 
to decay much more slowly in cortical bone 
than in trabecular bone during aging, increased 
odds of PD as a result of bias from faster reduc-
tions in bone lead among controls (because of 
relatively greater new bone formation) com-
pared with cases would be expected to be more 
pronounced for patella bone lead than for tibia 
bone lead. Our findings show no association 
between patella bone lead and PD and there-
fore suggest that this potential bias did not 
account for the association between tibia lead 
and PD. Furthermore, if this potential bias 
explained our results, then we would expect the 
association to be stronger for cases with longer 
PD duration, which was not the case.
An additional limitation is that our recruit-
ment process for both cases and controls was 
such that we cannot determine the participa-
tion rates for our study. The recruitment of 
controls by several distinct approaches could 
raise concern that one set of controls might 
drive the results, but arguing against this is the 
observation that our results were similar among 
different subsets of controls. It is possible that 
differences in bone lead measurements could be 
introduced by the use of two different KXRF 
machines, but because one machine was used 
exclusively on both cases and controls from the 
NAS, the inclusion of a term for NAS partici-
pants in our models as part of our adjustment 
for recruitment site would control for any such 
measurement differences by machine.
The use of spouse, in-law, and friend con-
trols can result in controls being more similar 
to cases for some variables—importantly, lead 
exposure—than would be found in the general 
target population. This similarity may explain 
the association between smoking and PD in 
our study—an adjusted OR per 10 pack-years 
of 0.86 (95% CI, 0.71–1.04), which is not as 
strong an inverse association as in other reports 
(Hernan et al. 2002), likely because smok-
ing behaviors tend to be concordant among 
spouses, relatives, and friends (Di Castelnuovo 
et al. 2009). As our smoking results illustrate, 
this bias is almost always toward the null; thus, 
if it also affects the results for lead exposure, 
our results would be more likely to be muted 
rather than spuriously large. In addition, we 
recruited most of the cases in our study from 
movement disorders clinics, and there tend to 
be differences between PD cases seen at clinics 
compared with a community sample of cases. 
PD cases seen in clinics have been reported 
to more likely be, for example, younger and 
male (Rybicki et al. 1995). These differences 
would be unlikely to introduce any referral 
bias in our study because we adjusted for these 
factors. However, clinic PD cases have also 
been reported to be more likely to have private 
health insurance, to be frequent users of health 
care, and to use hospital-based clinics for their 
primary health care (Rybicki et al. 1995). If 
these characteristics are also associated with 
lead exposure, bias could be introduced into 
our results. Indeed, if these characteristics are 
associated with lower lead exposure, then this 
referral bias may partly explain the attenuated 
results we found when including HCPOA and 
community controls.
In summary, in this large case–control 
study, we found evidence that higher cumu-
lative exposure to lead is associated with an 
increased risk of PD. Our data provide some 
of the strongest evidence to date for a role for 
lead in the development of PD.
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